Dr Ken Taylor, CEO of LCT, says, “We are encouraged to see efficacy data at the longer time point. We need to further analyse this encouraging result at future time points to assess NTCELL as a potential treatment for Parkinson’s disease.”
Nice to have a job monitoring till May 2019,,
Ann: NTCELL and Parkinsons trial update, page-4
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
-0.001(8.33%) |
Mkt cap ! $20.24M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.2¢ | 1.1¢ | $4 | 328 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 3812324 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 2278050 | 8 |
View Market Depth
| Last trade - 15.31pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
1.1¢ |
Change
-0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 1.1¢ | 1.2¢ | 1.1¢ | 396096 | ||
| Last updated 14.40pm 10/05/2024 ? | |||||
| 1AI (ASX) Chart |